BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation.

Turecek, P L; Bossard, M J; Graninger, M; Gritsch, H; Höllriegl, W; Kaliwoda, M; Matthiessen, P; Mitterer, A; Muchitsch, E-M; Purtscher, M; Rottensteiner, H; Schiviz, A; Schrenk, G; Siekmann, J; Varadi, K; Riley, T; Ehrlich, H J; Schwarz, H P; Scheiflinger, F

Turecek, P L; Bossard, M J; Graninger, M; Gritsch, H; Höllriegl, W; Kaliwoda, M; Matthiessen, P; Mitterer, A; Muchitsch, E-M; Purtscher, M; Rottensteiner, H; Schiviz, A; Schrenk, G; Siekmann, J; Varadi, K; Riley, T; Ehrlich, H J; Schwarz, H P; Scheiflinger, F.

Affiliation

Turecek PL; Baxter Innovations GmbH, Vienna, Austria. peter_turecek@baxter.com

Hamostaseologie ; 32 Suppl 1: S29-38, 2012.

Article de En | MEDLINE | ID: mdl-22961422

Sujet(s)

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links

Collection: 01-internacional Base de données: MEDLINE Sujet principal: Polyéthylène glycols / Facteur VIII / Conception de médicament / Hémophilie A / Liposomes Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Hamostaseologie Année: 2012 Type de document: Article Pays d'affiliation: Autriche

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links